Global Aptamers Market (2021 to 2026)

Dublin, Nov. 17, 2021 (GLOBE NEWSWIRE) — The “Aptamers Market by Product Type (DNA, RNA, XNA), Technology (SELEX), Application (Therapeutics, Diagnostics, R&D), End Users (Pharmaceutical & Biotechnology Companies, Academic & Government Research Institutes, CROs) – Global Forecast to 2026” report has been added to ResearchAndMarkets.com’s offering.

The aptamers market is valued at an estimated USD 151 million in 2021 and is projected to reach USD 342 million by 2026, at a CAGR of 17.7% during the forecast period.

The growth of the aptamers market is attributed to factors such as an increase in the number of clinical trials for the development of aptamer-based therapeutics, increase in awareness about advantages of aptamers as compared to antibodies, rising investment in pharmaceutical R&D, and rising prevalence of chronic and rare diseases to increase the demand for aptamer-based therapeutics and diagnostics.

Growth in the venture capital funding for research on aptamers and growing collaborations with research institutes and pharmaceutical companies are also expected to offer a wide range of growth opportunities to players in the market. On the other hand, low market acceptance as compared to antibodies is likely to restrain the market growth while shortage of skilled & trained professionals may challenge market growth to a certain extent.

SELEX is the largest end-user segment in the aptamers market in 2020.

Based on technology, the aptamers market is segmented into SELEX and other technologies. The SELEX technology segment dominated the market in 2020. The segment accounts for a large share of the aptamers market as SELEX is one of the most widely used technologies. The other technologies segment is expected to register the highest CAGR during the forecast period due to the increasing focus on developing technologies for aptamer selection.

The diagnostic segment is anticipated to witness the fastest growth during the forecast period.

Story continues

Based on the application, the aptamers market is segmented into therapeutics development, research & development, diagnostics, and other applications. In 2020, the therapeutics development segment dominated the market due to the increasing number of clinical trials evaluating aptamers for new therapies and collaborations among aptamer companies & prominent pharmaceutical and biotechnology firms. The diagnostic segment is projected to grow at the highest CAGR due to the increasing prevalence of chronic diseases and the development of new diagnostic kits to detect cancer and other diseases.

Asia Pacific region is anticipated to witness the fastest growth during the forecast period.

The aptamers market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is estimated to record the highest CAGR during the forecast period. This is attributed to the rising R&D activities on aptamers, the development of aptamer-based products, and the rising focus on drug discovery and development.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights
4.1 Aptamers Market Overview
4.2 North America: Aptamers Market Share, by Type & Country (2020)
4.3 Aptamers Market, by Type, 2021 Vs. 2026 (USD Million)
4.4 Aptamers Market Share, by End-user, 2020
4.5 Aptamers Market: Geographic Growth Opportunities

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Rising Number of Clinical Trials to Develop Aptamer-Based Therapeutics
5.2.1.2 Rising Awareness of the Advantages of Aptamers Over Antibodies
5.2.1.3 Investments in Pharmaceutical R&D
5.2.1.4 Rising Prevalence of Chronic and Rare Diseases
5.2.2 Restraints
5.2.2.1 Low Market Acceptance as Compared to Antibodies
5.2.3 Opportunities
5.2.3.1 Growth in the Venture Capital Funding for Research on Aptamers
5.2.3.2 Growing Collaborations with Research Institutes and Pharmaceutical Companies
5.2.4 Challenges
5.2.4.1 Shortage of Skilled & Trained Professionals
5.3 Impact of COVID-19 Outbreak on the Aptamers Market
5.4 Pipeline Analysis
5.5 Technology Analysis
5.6 Porters Five Forces Analysis
5.6.1 Threat of New Entrants
5.6.2 Threat of Substitutes
5.6.3 Bargaining Power of Suppliers
5.6.4 Bargaining Power of Buyers
5.6.5 Intensity of Competitive Rivalry
5.7 Ecosystem Analysis
5.8 Value Chain Analysis
5.9 Patent Analysis
5.9.1 Patent Publication Trends
5.9.2 Jurisdiction Analysis: Top Applicants (Countries) for Aptamer Patents

6 Aptamers Market, by Type
6.1 Introduction
6.2 DNA Aptamers
6.2.1 Increasing Use of DNA Aptamers and Their Wide Availability Boosts Segment Growth
6.3 Xna Aptamers
6.3.1 Focus on Developing Next-Generation Aptamers for Specific Targets to Boost Segment Growth
6.4 Rna Aptamers
6.4.1 Increasing Research Activities for the Use of Rna Aptamers Boosts Segment Growth

7 Aptamers Market, by Technology
7.1 Introduction
7.2 Selex
7.2.1 Selex is the Most Widely Used Technology for Aptamers Selection
7.3 Other Technologies

8 Aptamers Market, by Application
8.1 Introduction
8.2 Therapeutics Development
8.2.1 Prominent Players Offering Services for Therapeutics Development to Boost the Market Growth
8.3 Research & Development
8.3.1 Increasing Availability of Aptamers for Academic Research to Drive Market Growth
8.4 Diagnostics
8.4.1 The Increasing Prevalence of Diseases Such as Cancer and Product Launches are Projected to Drive the Segment Growth
8.5 Other Applications

9 Aptamers Market, by End-user
9.1 Introduction
9.2 Pharmaceutical & Biotechnology Companies
9.2.1 Prominent Players Offering Services for Drug Development to Drive Market Growth
9.3 Academic & Government Research Institutes
9.3.1 Collaborative Efforts Among Companies & Research Institutes Will Drive the Growth of the Market
9.4 Contract Research Organizations
9.4.1 Research Partnerships Between Pharma Players and Contract Organizations Drive Market Growth
9.5 Other End-users

10 Aptamers Market, by Region

11 Competitive Landscape
11.1 Introduction
11.2 Right-To-Win Approaches Adopted by Key Players
11.3 Market Ranking Analysis
11.4 Company Evaluation Matrix
11.4.1 Stars
11.4.2 Emerging Leaders
11.4.3 Pervasive Players
11.4.4 Participants
11.5 Competitive Benchmarking
11.5.1 Company Footprint (10 Companies)
11.5.2 Company Product & Service Footprint (10 Companies)
11.5.3 Company Technology Footprint (10 Companies)
11.5.4 Company Application Footprint (10 Companies)
11.5.5 Company End-User Footprint (10 Companies)
11.6 Competitive Scenario and Trends
11.6.1 Product & Service Launches
11.6.2 Deals

12 Company Profiles
12.1 Key Companies
12.1.1 Aptamer Group
12.1.2 Raptamer Discovery Group
12.1.3 Somalogic, Inc.
12.1.4 Aptamer Sciences, Inc.
12.1.5 Aptagen, LLC
12.1.6 Maravai Lifesciences
12.1.7 Kaneka Corporation
12.1.8 Neoventures Biotechnology Inc.
12.1.9 Aptus Biotech
12.1.10 Base Pair Biotechnologies
12.1.11 Amsbio
12.1.12 Novaptech
12.1.13 Bio-Techne
12.1.14 Aptitude Medical Systems
12.1.15 Raybiotech, Inc.
12.1.16 Alpha Diagnostic International, Inc.
12.1.17 Creative Biolabs
12.1.18 Creative Biogene
12.1.19 Vivonics Inc.
12.1.20 Iba Lifesciences GmbH
12.2 Other Players
12.2.1 Aptabharat Innovations Pvt. Ltd
12.2.2 Profacgen
12.2.3 Mediven
12.2.4 Pure Biologics Sa
12.2.5 Oak Biosciences, Inc.

13 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/qnurei

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900